IXICO PLC (AIM:IXI, OTC:PHYOF), the data analytics company delivering insights in neuroscience, said one of its clients has called an indefinite halt to a clinical trial.
The client unexpectedly received preclinical data and is suspending the trial while it completes further pre-clinical studies.
Contracted revenues for this trial represented £3.3mln of the company's order book as at the end of September, of which IXICO had expected to deliver £0.8mln in revenue in the current fiscal year.